Zevra Therapeutics, Inc.

ZVRA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$10.05+5.73%

2026-08-03

Financials

Valuation Metrics

Zevra Therapeutics, Inc.'s Market Cap is $594M. At end of 2025 it was $496M. Ranked #2730 of 3,112 in US market (top 88%), #1171 of 1,445 on NASDAQ (top 81%), #215 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$594M	US#2,730/3,112 Sec#215/269
Revenue	$122M	US#2,757/3,112 Sec#122/269
Net Income	$124M	US#1,509/3,112 Sec#51/269
Total Assets	$279M	US#2,919/3,112 Sec#222/269
Net Assets	$206M	US#2,727/3,112 Sec#197/269
Value
P/E	4.79x	US#38/3,112 Sec#5/269
P/B	2.89x	US#1,627/3,112 Sec#82/269
P/S	4.86x	US#2,242/3,112 Sec#76/269
EV/EBITDA	3.56x	US#82/3,112 Sec#8/269
FCF Yield	2.02%	US#1,954/3,112 Sec#71/269
Profitability
ROE	60.36%	US#93/3,112 Sec#11/269
ROA	44.59%	US#8/3,112 Sec#3/269
Op. Margin	-39.86%	US#2,760/3,112 Sec#112/269
Revenue Growth	77.54%	US#188/3,112 Sec#40/269
Financial Health
Debt Ratio	35.36%	US#393/3,112 Sec#114/269
Total Debt	$1M	US#2,926/3,112 Sec#243/269
FCF	$12M	US#2,198/3,112 Sec#82/269
Cash	$96M	US#2,238/3,112 Sec#182/269
Current Ratio	4.89x	US#480/3,112 Sec#146/269
Net Debt/EBITDA	-0.67x	US#391/3,112 Sec#25/269
Performance
1Y Return	-9.50%	US#2,375/3,112 Sec#211/269
1M Return	-28.08%	US#3,050/3,112 Sec#253/269
From 52W High	-33.14%	US#2,294/3,112 Sec#174/269
1Y MDD	-43.47%	US#2,126/3,112 Sec#157/269
Trading
Volume	1,722,787 shares	US#1,016/3,112 Sec#93/269
Trading Value	$17M	US#2,064/3,112 Sec#158/269
Per Share
EPS	$1.50	US#1,436/3,112 Sec#48/269
BPS	$2.80	US#2,439/3,112 Sec#164/269